LBL-024 for Injection: Clinical Trials

10 trials of LBL-024 for Injection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 recruiting. 10 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Recruiting 10
Phase 16Recruiting 6

Follow LBL-024 for Injection: new trials by email Literature Review of LBL-024 for Injection trials Research Report on LBL-024 for Injection

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
LBL-024 for Injection, Bevacizumab injection, Oxaliplatin injection - Metastatic Colorectal Carcinoma
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd3692026-09-282026-10-16
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
LBL-024 for Injection, Capecitabine tablets, Tislelizumab Injection - Advanced Solid Tumour
Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd1102026-04-132026-05-13
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection - Advanced Solid Tumour
Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd1102026-02-262026-05-18
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
LBL-024 for Injection, albumin-bound Paclitaxel injection, Toripalimab Injection - Triple Negative Breast Cancer
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd2202026-01-272026-02-12
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection - Ovarian Cancer
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd1802025-12-022026-08-13
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection - Advanced Solid Tumour
Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd1402025-10-202026-10-19
A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
LBL-024 for Injection, Toripalimab Injection - Advanced Melanoma
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd2802025-09-052026-10-21
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection - Advanced Solid Tumour
Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd2502025-06-112026-08-27
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
LBL-024 for Injection, Etoposide Injection, Carboplatin Injection - Advanced Neuroendocrine Carcinoma
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd1782023-12-082026-03-12
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
LBL-024 for Injection - Advanced Solid Tumor
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd3962022-01-062026-06-30

Conditions studied

Colorectal Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Nanjing Leads Biolabs Co.,Ltd (10)

Countries

China (10)

Top investigators

Lin Shen (2)  ·  Ruihua Xu (1)  ·  Yu Chen (1)